-
11.发明公开소듐 2-메르캅토에탄 설포네이트를 삼투압 조절제로서 함유하는 생체투여 또는 미용성형용 생분해성 고분자 조성물 审中-实审用于管理生活体的生物可降解聚合物或用于作为动物剂的含有2-巯基乙酸乙酯的化妆品
公开(公告)号：KR1020160102723A
公开(公告)日：2016-08-31
申请号：KR1020150025145
申请日：2015-02-23
Applicant: (주)아모레퍼시픽
IPC: A61K8/46 , A61K8/73 , A61K31/185
CPC classification number: A61K8/46 , A61K8/73 , A61K31/185 , A61K9/0019 , A61Q19/00
Abstract: 본발명은소듐 2-메르캅토에탄설포네이트를삼투압조절제로서함유하는조성물에관한것으로서, 보다상세하게는소듐 2-메르캅토에탄설포네이트를삼투압조절제로서함유함으로써삼투압조절이용이하게이루어지면서이에추가적으로멸균전후물성이일정하게유지되는조성물, 특히히알루론산또는히알루론산의유도체를포함하는생체투여용생분해성고분자조성물에관한것이다.
Abstract translation: 本发明涉及含有2-巯基乙磺酸钠作为渗透压调节剂的组合物。 更具体地说，本发明涉及一种含有2-巯基乙磺酸钠作为渗透压调节剂的组合物，其能够以容易的方式进行渗透压调节，同时在灭菌前后保持稳定的材料性质。 特别地，本发明涉及含有透明质酸或其衍生物的生物可降解聚合物组合物。
-
公开(公告)号：KR1020100052253A
公开(公告)日：2010-05-19
申请号：KR1020080111190
申请日：2008-11-10
Applicant: (주)아모레퍼시픽
CPC classification number: A61K31/41 , A61K9/0053 , A61K9/2095
Abstract: PURPOSE: A method for manufacturing a solid oral formulation containing valsartan is provided to effectively obtain an oral formulation having excellent disintegration force and dissolution rate. CONSTITUTION: A method for manufacturing a solid oral formulation containing valsartan comprises: a step of contacting valsartan and pharmaceutically acceptable additive with binding solution; a step of drying resultant; a step of granulating the dried resultant; and a step of mixing the granule with disintegrant and lubricant. The binding solution is water, or mixture of water and ethanol. The disintegrant is crospovidone.
Abstract translation: 目的：提供一种制备含缬沙坦固体口服制剂的方法，以有效获得具有优异的崩解力和溶出率的口服制剂。 构成：制备含缬沙坦的固体口服制剂的方法包括：将缬沙坦和药学上可接受的添加剂与结合溶液接触的步骤; 干燥结果的步骤; 造粒干燥物的步骤; 以及将颗粒与崩解剂和润滑剂混合的步骤。 结合溶液是水，或水和乙醇的混合物。 崩解剂是交聚维酮。
-
公开(公告)号：KR1020080004075A
公开(公告)日：2008-01-09
申请号：KR1020060062558
申请日：2006-07-04
Applicant: (주)아모레퍼시픽
CPC classification number: A61K47/6951 , A61K9/0002 , A61K9/0012 , A61K9/1652
Abstract: A sustained-release porous microparticle for pulmonary delivery of a protein drug is provided to reduce destruction of microparticles by macrophages by having suitable particle size, improve stability and distribution uniformity of a protein drug, and release the drug for a long period of time without initial burst. A sustained-release porous microparticle comprises a protein drug as an active ingredient, cyclodextrin derivatives, viscous hydrophilic polymer, biodegradable polymer, sucrose acetate isobutyrate and aqueous coating materials, and has an average particle diameter of 5-100 mum. A process for preparing the sustained-release porous microparticle comprises the steps of: (1) solubilizing cyclodextrin derivatives, viscous hydrophilic polymer and a protein drug in water to prepare an inner water phase; (2) adding biodegradable polymer and sucrose acetate isobutyrate into organic solvent to prepare an organic phase; (3) mixing the inner water phase with the organic phase to prepare a first emulsion; and (4) spraying the first emulsion to an outer aqueous continuous phase containing aqueous coating materials.
Abstract translation: 提供用于肺部递送蛋白质药物的缓释多孔微粒，以通过具有适当的粒径，改善蛋白质药物的稳定性和分布均匀性，并且长时间释放药物以减少巨噬细胞对微粒的破坏，而没有初始 爆裂。 持续释放多孔微粒包含蛋白质药物作为活性成分，环糊精衍生物，粘性亲水性聚合物，可生物降解聚合物，蔗糖乙酸异丁酸酯和水性涂料，平均粒径为5-100μm。 制备缓释多孔微粒的方法包括以下步骤：（1）将环糊精衍生物，粘性亲水性聚合物和蛋白质药物溶于水中制备内水相; （2）将可生物降解的聚合物和蔗糖乙酸异丁酯加入到有机溶剂中以制备有机相; （3）将内水相与有机相混合以制备第一乳液; 和（4）将第一乳液喷涂到含有水性涂料的外部含水连续相中。
-
Patent Agency Ranking
公开(公告)号：KR1020150001070A
公开(公告)日：2015-01-06
申请号：KR1020130073708
申请日：2013-06-26
Applicant: (주)아모레퍼시픽
IPC: A61K31/715 , A61K31/70 , A61K8/73 , A61P17/00
CPC classification number: A61K31/737 , A23L29/30 , A23V2200/318 , A61K8/73 , A61K9/0019 , A61K31/728
Abstract: 본 명세서는 글루코스아미노글라이칸의 하나인 콘드로이친설페이트와 히알루론산을 함유하는 콜라겐의 생성을 촉진하는 조성물에 관한 것으로서, 피부 조직에 처리하였을 때 뛰어난 콜라겐 생성 효과를 나타내고, 피부 조직을 수복시키는 것을 촉진 하는 조성물에 관한 것이다.
Abstract translation: 本说明书涉及促进产生胶原蛋白的组合物，包括作为一种糖胺聚糖的硫酸软骨素和透明质酸，并且涉及当组合物处理皮肤组织时对胶原产生具有优异效果的组合物 并促进皮肤组织的恢复。
-
公开(公告)号：KR1020130060684A
公开(公告)日：2013-06-10
申请号：KR1020110126881
申请日：2011-11-30
Applicant: (주)아모레퍼시픽
IPC: A61N1/18 , A61M5/178 , A61M5/158 , A61K31/575
Abstract: PURPOSE: A lipolysis kit is provided to alleviate pain, bruise, red spots, edema, pruritus, etc. which are caused by a lipolysis shot by having injection liquid containing a low frequency stimulator and a lipolysis material. CONSTITUTION: A lipolysis kit comprises a lipolysis material and a low frequency stimulator. A lipolysis means includes a composition for lipolysis, and a transfer mechanism to transfer the composition for lipolysis to a target area. The composition for lipolysis includes at least one or more of lipid, bile acid or salt thereof, a beta adrenalin receptor effector, and hyaluronidase. The composition for lipolysis contains at least one or more of deoxycholic acid, cholic acid, chenodeoxycholic acid, 7-alpha-dehydroxylate chenodeoxycholic acid, litho cholic acid, ursodeoxycholic acid, dihydroxy taurine acid, trihydroxy taurine acid or salt thereof, phosphatidylcholine, hyaluronidase, aminophylline, theophylline, isoproterenol, and salbutamol and salmeterol or salt thereof. The transfer mechanism includes at least one of a syringe containing one needle, a syringe containing multiple needles, a patch, and a micro needle. [Reference numerals] (AA) Δupper arm girth(cm); (BB) PPC + low frequency wave; (CC) 50% improvement; (DD) -after 2-3 days, measurement of upper arm girth
Abstract translation: 目的：提供脂解酶，以减轻由含有低频刺激剂和脂肪分解物质的注射液引起的脂解引起的疼痛，瘀伤，红点，水肿，瘙痒等。 构成：脂肪分解试剂盒包含脂肪分解物质和低频刺激剂。 脂肪分解方法包括用于脂肪分解的组合物和将脂肪分解组合物转移到目标区域的转移机理。 用于脂解的组合物包括至少一种或多种脂质，胆汁酸或其盐，β肾上腺素受体效应物和透明质酸酶。 用于脂解的组合物含有脱氧胆酸，胆酸，鹅脱氧胆酸，7-α-脱羟酸甲酯脱氧胆酸，石蜡酸，熊去氧胆酸，二羟基牛磺酸，三羟基牛磺酸或其盐，磷脂酰胆碱，透明质酸酶， 氨茶碱，茶碱，异丙肾上腺素和沙丁胺醇以及沙美特罗或其盐。 传送机构包括至少一个包含一个针的注射器，包含多个针的注射器，贴片和微针。 （附图标记）（AA）Δupper臂围（cm）; （BB）PPC +低频波; （CC）50％改善; （DD） - 2-3天后，测量上臂周长
-
公开(公告)号：KR1020130057640A
公开(公告)日：2013-06-03
申请号：KR1020110123485
申请日：2011-11-24
Applicant: (주)아모레퍼시픽
CPC classification number: C08L5/08 , A61K9/06 , A61K47/36 , A61L15/28 , A61L27/20 , A61L2400/06 , C08B37/0072 , A61K9/10 , A61K47/50
Abstract: PURPOSE: A method for preparing a water-insoluble gel composition is provided to minimize molecular weight reduction of polysaccharides using a small amount of a crosslinking agent and to ensure excellent strength and stability. CONSTITUTION: A method for preparing a water-insoluble gel composition comprises: a step of mixing water-soluble polysaccharides, an epoxy crosslinking agent, a basic compound, and a solvent; and a step of drying the mixture under vacuum at 1-30 deg. C to remove the solvent. The vacuum pressure is 1-30 mmHg. The solvent is removed by concentrating the water soluble polysaccharides in a concentration of 50-99 wt%. The molecular weight of the water soluble polysaccharides is 500-5,000 kDa. [Reference numerals] (AA) Volume of gel(%); (BB) Example 11
Abstract translation: 目的：提供一种制备水不溶性凝胶组合物的方法，以尽量减少使用少量交联剂的多糖的分子量降低并确保优异的强度和稳定性。 构成：制备水不溶性凝胶组合物的方法包括：将水溶性多糖，环氧交联剂，碱性化合物和溶剂混合的步骤; 以及在1-30度的真空下干燥混合物的步骤。 C去除溶剂。 真空压力为1-30mmHg。 通过浓缩50-99重量％的水溶性多糖来除去溶剂。 水溶性多糖的分子量为500-5,000kDa。 （标号）（AA）凝胶体积（％）; （BB）实施例11
-
公开(公告)号：KR100908517B1
公开(公告)日：2009-07-20
申请号：KR1020060062558
申请日：2006-07-04
Applicant: (주)아모레퍼시픽
Abstract: 본 발명은 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그 제조방법에 관한 것으로, 본 발명에 따른 서방형 다공성 미세입자는 20 ㎛내외의 충분한 입경 크기로 대식세포에 의한 파괴를 줄이고, 사이클로덱스트린 유도체를 적정량 함유하여 다공성을 확보함은 물론 단백질 약물을 안정하고 균일하게 함유하여 폐심부까지 약물을 이동시킬 수 있으며, 수크로스 아세테이트 이소부틸레이트(SAIB)를 함유함으로써 약물의 봉입효율이 우수할 뿐 아니라 약물의 초기 방출을 억제하여 장기간, 길게는 일주일간 지속 방출이 가능하므로 호흡기계 약물 전달 제형으로 유용하게 활용될 수 있다.
Abstract translation: 提供一种用于肺部递送蛋白质药物的缓释多孔微粒，以通过具有合适的粒径来减少巨噬细胞对微粒的破坏，改善蛋白质药物的稳定性和分布均匀性，并且在没有初始时间的情况下长时间释放药物 爆裂。 缓释型多孔微粒含有蛋白质药物作为有效成分，环糊精衍生物，粘性亲水性聚合物，生物降解性聚合物，醋酸异丁酸蔗糖酯和水性涂料，平均粒径为5〜100μm。 制备缓释多孔微粒的方法包括以下步骤：（1）将环糊精衍生物，粘性亲水聚合物和蛋白药物溶于水中以制备内水相; （2）将可生物降解的聚合物和乙酸异丁酸蔗糖酯加入有机溶剂中以制备有机相; （3）将内部水相与有机相混合以制备第一种乳液; 和（4）将第一种乳液喷涂到含水涂料的外部含水连续相上。
-
公开(公告)号：KR1020080076440A
公开(公告)日：2008-08-20
申请号：KR1020070016352
申请日：2007-02-16
CPC classification number: A61K9/2054 , A61K9/1635 , A61K9/1652 , A61K9/1694 , A61K9/205 , A61K9/2077 , A61K31/4709
Abstract: A controlled-release preparation containing cilostazol is provided to minimize side effects such as headache due to immediate release of cilostazol, and improve compliance of patient by maintaining effective blood concentration of cilostazol and reducing dosage frequency. A controlled-release preparation contains 10-80 wt.% of cilostazol or its pharmaceutically acceptable salt, 0.1-50 wt.% of solubilizer and 5-80 wt.% of erodible hydrogel-forming material selected from polyethylene oxide, hydroxyalkylcellulose, hydroxypropylalkylcellulose, polyvinylalcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, propyleneglycol alginate, carbopol, sodium alginate, xanthan gum, locust bean gum, cellulose gum, gellan gum, tragacanth gum, karaya gum, guar gum, acacia gum and a mixture thereof. A method for preparing the controlled-release preparation containing cilostazol comprises the steps of: (1) mixing cilostazol or its pharmaceutically acceptable salt with solubilizer and granulating the mixture by solid dispersion to prepare solubilized drug granules; and (2) mixing the solubilized drug granules with erodible hydrogel-forming material and granulating the mixture.
Abstract translation: 提供含有西洛他唑的控释制剂以最小化由于西洛他唑立即释放引起的头痛等副作用，并通过维持西洛他唑有效血药浓度和降低剂量频率来提高患者的依从性。 控释制剂含有10-80重量％的西洛他唑或其药学上可接受的盐，0.1-50重量％的增溶剂和5-80重量％的可溶性水凝胶形成材料，其选自聚环氧乙烷，羟烷基纤维素，羟丙基烷基纤维素， 聚乙烯醇，聚乙烯吡咯烷酮，羧甲基纤维素钠，藻酸丙二醇酯，聚羧乙烯，藻酸钠，黄原胶，刺槐豆胶，纤维素胶，结冷胶，黄蓍胶，刺梧桐胶，瓜尔胶，阿拉伯树胶及其混合物。 制备含有西洛他唑的控释制剂的方法包括以下步骤：（1）将西洛他唑或其药学上可接受的盐与增溶剂混合并通过固体分散体制粒混合物以制备溶解的药物颗粒; 和（2）将溶解的药物颗粒与可侵蚀的水凝胶形成材料混合并将混合物制粒。
-
-
-
-
-
-
-
Search Results
18
records
(took 0.054 seconds)
